# Recurrent uveitic macular edema managed with intravitreal faricimab injection

## TL;DR

A 63-year-old woman with recurring eye swelling due to a rare eye condition was successfully treated with a new drug called faricimab.

## Contribution

This case suggests faricimab may be effective for treatment-resistant uveitic macular edema.

## Key findings

- One dose of faricimab led to complete resolution of uveitic macular edema.
- The effect was maintained for three months without recurrence.
- The drug's dual action on angiopoietin-2 and vascular endothelial growth factor A may explain its success.

## Abstract

To present a case of recurrent uveitic macular edema (UME) treated with intravitreal faricimab injection.

Single case report from a tertiary referral center.

A 63-year-old Caucasian female presenting with recurrent UME due to birdshot chorioretinopathy (BSCR) in both eyes. UME had been treated with multiple agents including intravenous methylprednisone, posterior subtenons and intravitreal triamcinolone acetonide injection, dexamethasone implant, mycophenolate mofetil, and adalimumab with limited improvement and development of intolerance. Moreover, optical coherence tomography also revealed recurrence of UME with subretinal fluid in both eyes. After treatment with one dose of intravitreal faricimab injection, complete resolution of UME was achieved and maintained for three months.

The findings of this case hint towards the potential simultaneous effect of angiopoietin-2 blockade along with vascular endothelia growth factor A inhibition by faricimab in managing treatment-resistant UME. Nonetheless, more studies focusing on the role of intravitreal faricimab in UME are required.